董事离职管理制度 第一章 总则 第一条 为规范山西科新发展股份有限公司（以下简称"公司"）董 事离职程序，确保公司治理结构的稳定性和连续性，维护公司及股东的合 法权益，根据《公司法》《证券法》 《上市公司治理准则》《上海证券交易 所股票上市规则》《公司章程》等相关规定，结合公司实际情况，制定本 制度。 第二条 本制度适用于公司董事（含独立董事）因任期届满、辞职、 被解除职务或其他原因离职的情形。 第三条 公司董事离职管理应遵循以下原则： （一）合法合规原则：严格遵守国家法律法规、监管规定及《公司章 程》的要求； （二）公开透明原则：及时、准确、完整地披露董事离职相关信息； （三）平稳过渡原则：确保董事离职不影响公司正常经营和治理结构 的稳定性； （四）保护股东权益原则：维护公司及全体股东的合法权益。 第二章 离职情形与程序 第四条 公司董事离职包含任期届满未连任、主动辞职、被解除职务 以及其他导致董事实际离职等情形。 第五条 辞职程序：公司董事可以在任期届满以前辞职，董事辞职应 当向公司提交书面辞职报告，辞职报告中应说明辞职原因，公司收到辞职 报告之日辞职生效。 第六条 如存在下列情形，在改选出的董事就任前， ...

Core Viewpoint - Central Huijin has heavily invested in five low-priced stocks, indicating a potential new wave of market growth, with expectations of significant returns similar to past investments [1][3]. Group 1: Central Huijin's Investment Strategy - Central Huijin has a history of successful investments, such as in Luzhou Laojiao in 2015, Northern Huachuang in 2018, and Changchun Gaoxin in 2019, each achieving tenfold increases [3]. - The current focus is on five low-priced stocks that are expected to experience substantial growth, potentially creating the next tenfold bull stock [3]. Group 2: Specific Stocks Identified - The first stock is Shanghai Construction, a leader in the construction industry, with Central Huijin holding 52.8 million shares [4]. - The second stock is Wenfeng Shares, a leading retail company in Shanghai, with Central Huijin holding 21.95 million shares [5]. - The third stock is Shoukai Shares, which has first-class real estate development qualifications, with Central Huijin holding 38.41 million shares [6]. - The fourth stock is Zhongheng Group, a top profit-generating company in the traditional Chinese medicine industry, with Central Huijin holding 49.78 million shares [7]. - The fifth stock is a global leader in nuclear power engineering, with orders amounting to 44 billion yuan, and has seen significant increases in holdings from both Central Huijin and foreign investors [7].

Core Insights - Zhongheng Group has released its 15th Social Responsibility Report, highlighting its practices in rural revitalization, green low-carbon transformation, and ensuring public welfare, receiving multiple honors including recognition in the ESG Pioneer 100 Index and as an excellent practice case for sustainable development in 2024 [1] Group 1: Green Development and Low-Carbon Transformation - The company is committed to green development, aligning with the national "dual carbon" goals, and has invested in energy conservation, emission reduction, clean production, and renewable energy utilization [1] - Zhongheng promotes green pest control and wild-simulated planting techniques, and is establishing a rescue base for the national second-level protected plant, promoting a green ecological circle for traditional Chinese medicine [1] - The company extends its environmental protection philosophy through activities like World Environment Day and tree planting [1] Group 2: Social Responsibility and Health Care - Zhongheng actively responds to national policies, with multiple products renewing contracts or winning bids in national and provincial centralized procurement, enhancing the accessibility of clinical medications and reducing patient burdens [1] - The company explores a "industry + technology + public welfare" model for rural revitalization, supporting the construction of traditional Chinese medicine material bases to increase farmers' income [1] - Zhongheng integrates intangible cultural heritage techniques with modern production technology to develop new products like sugar-free Liubao tea and black bean milk [1] - The company engages in volunteer services such as the Zhongheng Scholarship, Mother's Smile Initiative, and the Elderly and Children Care Project, continuously delivering warmth to society [1] Group 3: Corporate Governance and Development - Zhongheng focuses on modernizing its governance system, continuously improving its governance structure and establishing a long-term shareholder return mechanism [2] - Since its listing, the company has distributed a total of 2.941 billion yuan in dividends and repurchased nearly 173 million shares, demonstrating confidence in its corporate value [2] - In 2024, Zhongheng plans to establish three new provincial-level research platforms and has been approved for two Guangxi Natural Science Fund projects [2] - The company is advancing the development of innovative traditional Chinese medicine products and has received approvals for multiple drug varieties, solidifying its position in the industry [2] - Zhongheng aims to maintain a pragmatic approach, collaborating with partners to contribute to comprehensive reform and the modernization of China [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600252 证券简称：中恒集团 公告编号：临2025-56 广西梧州中恒集团股份有限公司 关于2025年以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）于2025年1月24日和2025年2月26日分 别召开第十届董事会第二十五次会议和2025年第一次临时股东大会，会议审议通过了《中恒集团关于 2025年以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金或自筹资金，以不超过3.80 元/股回购公司发行的人民币普通股（A股）股票，用于注销并减少公司注册资本。回购资金总额为不低 于人民币30,000.00万元（含）且不超过人民币50,000.00万元（含）。回购期限为自2025年2月26日召开 的股东大会审议通过回购方案之日起不超过6个月。具体内容详见公司于2025年4月2日在上海证券交易 所网站披露的《中恒集团关于2025年以集中竞价交易方式回购公司股份的回 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-56 广西梧州中恒集团股份有限公司 关于 2025 年以集中竞价交易方式回购公司股份 的进展公告 一、回购股份的基本情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）于 2025 年 1 月 24 日和 2025 年 2 月 26 日分别召开第十届董事会第二十五次会议和 2025 年第一次临时股东大会，会议审议通过了《中恒集团关于 2025 年以集中竞价交易 方式回购股份方案的议案》，同意公司使用自有资金或自筹资金，以不超过 3.80 元 /股回购公司发行的人民币普通股（A 股）股票，用于注销并减少公司注册资本。 回购资金总额为不低于人民币 30,000.00 万元（含）且不超过人民币 50,000.00 万 元（含）。回购期限为自 2025 年 2 月 26 日召开的股东大会审议通过回购方案之日 起不超过 6 个月。具体内容详见公司于 2025 年 4 月 2 日在上海证券交易所网站披 露的《中恒集团关于 2025 年以集中竞价交易方式回购公司股份的回购报告书》（公 告编号：临 2025-35）。 1 二、回购股份的进展情 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-55 广西梧州中恒集团股份有限公司 关于控股股东筹划公司控股权内部调整的提示性公告 ●广西梧州中恒集团股份有限公司（以下简称"公司"）控股股东广西投资 集团有限公司（以下简称"广投集团"）拟以其所持有的公司 859,343,587 股（占 公司总股本的 25.94%）无限售条件流通股股份对其控股公司广西投资集团金融 控股有限公司（以下简称"广投金控"）进行增资扩股（以下简称"本次交易"）。 ●目前，广投集团为广投金控的间接控股股东，广投集团、广投金控和公司 的实际控制人均为广西壮族自治区国有资产监督管理委员会（以下简称"广西国 资委"），本次交易属于同一控制下的国有股权变动。本次交易完成后，公司控 股股东将变更为广投金控，公司实际控制人仍为广西国资委。 ●上述事项尚处于筹划阶段，尚需履行国资审批程序及相关法定程序。截至 本公告披露日，广投集团与广投金控尚未签订相关协议。敬请广大投资者理性投 资并注意投资风险。 一、本次交易的基本情况 公司于 2025 年 5 月 30 日收到控股股东广投集团的通知，广投集团拟以其所 持有的公司 859,343 ...

Group 1 - The company, Chongqing Laimei Pharmaceutical Co., Ltd., announces that its indirect controlling shareholder, Guangxi Investment Group Co., Ltd., plans to increase capital in Guangxi Investment Group Financial Holding Co., Ltd. by transferring 859,343,587 shares of its direct controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd., which accounts for 25.94% of Zhongheng Group's total share capital [1][2] - After the transaction, Guangxi Investment Group Financial Holding Co., Ltd. will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the actual controller will still be the Guangxi State-owned Assets Supervision and Administration Commission [1][2] - The transaction is still in the planning stage and requires approval from state-owned assets authorities and other legal procedures [1][3] Group 2 - Prior to the transaction, Zhongheng Group is the direct controlling shareholder, and Guangxi Investment Group is the indirect controlling shareholder, with the actual controller being the Guangxi State-owned Assets Supervision and Administration Commission [2] - The transaction will not affect the company's normal production and operational activities, as it is a change of state-owned equity under the same control [2]

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-55 广西梧州中恒集团股份有限公司 关于控股股东筹划公司控股权内部调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●广西梧州中恒集团股份有限公司（以下简称"公司"）控股股东广西投资 集团有限公司（以下简称"广投集团"）拟以其所持有的公司 859,343,587 股（占 公司总股本的 25.94%）无限售条件流通股股份对其控股公司广西投资集团金融 控股有限公司（以下简称"广投金控"）进行增资扩股（以下简称"本次交易"）。 本次交易前，公司控股股东为广投集团，其直接持有公司 859,343,587 股（占 公司总股本的 25.94%）无限售条件流通股股份，并通过全资子公司广西广投医 1 药健康产业集团有限公司间接持有公司 104,253,215 股（占公司总股本的 3.15%） 无限售条件流通股股份。公司实际控制人为广西国资委。 本次交易完成后，公司控股股东将变更为广投金控，广投金控将直接持有公 司 859,343,587 股（占 ...

Group 1 - The core point of the article is that the indirect controlling shareholder of Laimei Pharmaceutical, Guangtou Group, plans to increase capital in Guangtou Jinkong by using its 859 million shares of Zhongheng Group, which accounts for 25.94% of Zhongheng Group's total share capital [1] - This transaction is classified as a change in state-owned equity under the same control [1] - After the completion of the transaction, Guangtou Jinkong will become the indirect controlling shareholder of Laimei Pharmaceutical, while Zhongheng Group will remain the direct controlling shareholder [1] Group 2 - The actual controller of Laimei Pharmaceutical will still be the Guangxi State-owned Assets Supervision and Administration Commission [1] - The equity change is currently in the planning stage and requires approval from state-owned assets authorities and other legal procedures [1]

Group 1 - The National Financial Regulatory Administration and the China Securities Regulatory Commission announced a series of financial policy measures to support market stability and expectations [1] - Central Huijin, a vice-ministerial level central enterprise, has an asset scale exceeding 10 trillion yuan after the merger of three major Asset Management Companies (AMCs) into China Investment Corporation [3] - Central Huijin's investment acumen has been validated multiple times in the market [4] Group 2 - Central Huijin has made significant investments in companies with high growth potential, including six leading firms in their respective fields [5] - The first company is Guodian Power, which has a diversified business model and is developing technology in nuclear power [5] - The second company is Gehua Cable, which operates the world's largest interactive digital TV platform and is considered a stable asset in communication infrastructure [6] - The third company is Sheneng Co., which dominates the natural gas and electricity sectors in Shanghai [7] - The fourth company is Zhongheng Group, known for its influential cardiovascular and oncology medications, with potential for valuation recovery [8] - The fifth company is Suzhou High-tech, the only A-share listed company under the Suzhou High-tech Zone government, focusing on new industry investment and urban development services [9] - The sixth company is a leading domestic industrial rigging manufacturer, with a stable market share and a large customer base across various sectors [10]